BeyondSpring reports AACR preclinical data on Plinabulin boosting ADC response rates

• BeyondSpring reported new preclinical data at AACR 2026 showing Plinabulin improved antitumor activity when combined with approved ADCs T-DXd or Dato-DXd.
• Results were already presented at AACR 2026, including findings with or without a PD-1 inhibitor.
• Study outcomes showed more durable tumor control in models, supporting a strategy to raise response depth versus ADC regimens alone.
• Safety signals in animals improved, aligning with prior clinical experience that Plinabulin can reduce chemotherapy-related neutropenia that can disrupt dosing.
• BeyondSpring positioned planned 442-patient DUBLIN-4 confirmatory Phase 3 trial as next clinical step, with AACR data supporting future ADC-combination studies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BeyondSpring Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604220700PRIMZONEFULLFEED9694721) on April 22, 2026, and is solely responsible for the information contained therein.